InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
JENA, Germany, March 20, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics…
1,149€
-1,03%
Echtzeit-Aktienkurs InflaRX N.V.
Bid:
Ask:
Nachrichten zur InflaRX N.V. Aktie
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering…
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics…
InflaRx Aktie: Starkes Vertrauen am Markt!
Die InflaRx N.V., ein biopharmazeutisches Unternehmen mit Sitz in Jena, verzeichnet bedeutende Fortschritte in seinen klinischen Studien. Der Hauptfokus liegt…
InflaRx Aktie: Fortschritte in klinischen Studien erwartet
Die InflaRx N.V., ein biopharmazeutisches Unternehmen mit Fokus auf entzündungshemmende Therapien, verzeichnet aktuell eine stabile Entwicklung an der Börse. Mit…
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics…
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics…
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics…
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics…